Pfizer pneumonia shots gain ACIP endorsement for wider indication

The Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention has voted to recommend the broader use of Pfizer Inc.'s $PFE (+1,18%) pneumococcal vaccine, PREVNAR 20, for adults aged 50 and above.

This expanded recommendation also includes adults aged 19-49 with certain underlying conditions or risk factors who have not previously received a pneumococcal conjugate vaccine (PCV) or whose vaccination history is unknown.

The recommendation awaits final approval from the CDC director and the Department of Health and Human Services.

PREVNAR 20 is the next-generation pneumococcal conjugate vaccine from Pfizer, containing capsular polysaccharide conjugates for 13 serotypes already included in its Prevnar 13 vaccine, plus seven additional serotypes associated with high case-fatality rates, antibiotic resistance, and/or meningitis.

The vaccine received FDA approval on June 8, 2021, for the prevention of IPD and pneumococcal pneumonia in adults aged 18 years and older. On September 30, 2022, the FDA approved the addition of information in the PREVNAR 20 prescribing information regarding coadministration with an influenza vaccine in adults aged 65 years or older.

SRC : Pfizer Press Statement